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GABA receptors within the mesolimbic circuitry have been
proposed to play a role in regulating alcohol-seeking behaviors
in the alcohol-preferring (P) rat. However, the precise GABAA
receptor subunit(s) mediating the reinforcing properties of EtOH
remains unknown. We examined the capacity of intrahip-
pocampal infusions of an a5 subunit-selective (;75-fold) ben-
zodiazepine (BDZ) inverse agonist [i.e., RY 023 (RY) (tert-butyl
8-(trimethylsilyl) acetylene-5,6-dihydro-5-methyl-6-oxo-4H-
imidazo [1,5a] [1,4] benzodiazepine-3-carboxylate)] to alter le-
ver pressing maintained by concurrent presentation of EtOH
(10% v/v) and a saccharin solution (0.05% w/v). Bilateral
(1.5–20 mg) and unilateral (0.01–40 mg) RY dose-dependently
reduced EtOH-maintained responding, with saccharin-maintained
responding being reduced only with the highest doses (e.g., 20
and 40 mg). The competitive BDZ antagonist ZK 93426 (ZK) (7 mg)
reversed the RY-induced suppression on EtOH-maintained re-
sponding, confirming that the effect was mediated via the BDZ site
on the GABAA receptor complex. Intrahippocampal modulation of
the EtOH-maintained responding was site-specific; no antago-
nism by RY after intra-accumbens [nucleus accumbens (NACC)]
and intraventral tegmental [ventral tegmental area (VTA)] infusions
was observed. Because the VTA and NACC contain very high
densities of a1 and a2 subunits, respectively, we determined
whether RY exhibited a “negative” or “neutral” pharmacological
profile at recombinant a1b3g2, a2b3g2, and a5b3g2 receptors
expressed in Xenopus oocytes. RY produced “classic” inverse
agonism at all a receptor subtypes; thus, a neutral efficacy was not
sufficient to explain the failure of RY to alter EtOH responding in
the NACC or VTA. The results provide the first demonstration that
the a5-containing GABAA receptors in the hippocampus play an
important role in regulating EtOH-seeking behaviors.
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Pharmacological studies support an involvement of GABAA re-
ceptor mechanisms in regulating EtOH-seeking behaviors (June
et al., 1998a,b; McBride and Li, 1998). Direct infusion of negative
GABAergic modulators [e.g., GABAA antagonists and benzodi-
azepine (BDZ) inverse agonists] in the extended amygdala and its
afferent projection sites have provided convincing evidence sup-
porting the role for GABAergic mechanisms in alcohol euphoric
properties (Hodge et al., 1995; June et al., 1998a,b; Koob et al.,
1998). However, these compounds are “nonselective” GABA
antagonists and are therefore not capable of dissecting out po-
tential roles of specific GABAA receptor subunits in regulating
EtOH-seeking behaviors. Furthermore, the remarkable heteroge-
neity in many traditional EtOH reward substrates (Fritschy and
Mohler, 1995) have precluded study of the precise GABAA sub-
unit(s) mediating EtOH-seeking behavior.
RY 023 (RY) [tert-butyl 8-(trimethylsilyl) acetylene-5,6-
dihydro-5-methyl-6-oxo-4H-imidazo [1,5a] [1,4] benzodiazepine-
3-carboxylate] is one of a series of 8-substituted imidazobenzo-
diazepine inverse agonists (Lui et al., 1995, 1996; Skolnick et al.,
1997) developed from the anti-EtOH agent Ro 15–4513 (Suzdak
et al., 1986). RY exhibits both high affinity (Ki of ;2.7 nM) and
selectivity (;75-fold) at recombinant GABAA receptors com-
posed of a5b2g2 subunits (Lui et al., 1996). At recombinant
a5b2g2 receptors expressed in Xenopus oocytes, it produces a
small reduction in GABA binding (;25 6 5%), and its convul-
sant activity is seen only with high doses (CD50 $ 40 mg/kg). This
contrasts the efficacy profile common to the nonselective negative
GABAergic modulators [e.g., bicuculline, 2-(3-carboxypropyl)-3-
amino-6-(4methoxyphenyl)pyridazinium bromide, and picrotox-
in] (Lui et al., 1995, 1996). Thus, RY represents an “ideal”
pharmacological tool to explore the role of the a5 subunit in the
neurobehavioral effects of alcohol.
Although the a5 subunits are minor constituents of the total
GABAA receptor pool, immunocytochemical, in situ hybridiza-
tion, and radioligand binding studies show that the CA1, CA2,
and CA3 fields are enriched in this subunit compared with other
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brain areas (Wisden et al., 1992; Fritschy and Mohler, 1995; Sur
et al., 1999). The CA1 and CA3 hippocampal fields are particu-
larly interesting candidate sites for the study of alcohol-motivated
behaviors because projections from the CA1 and CA3 fields, via
the subiculum, innervate several putative EtOH reward substrates
[e.g., nucleus accumbens (NACC), amygdala, bed nucleus of the
stria terminalis, hypothalamus, and olfactory tubercle] (Kelley
and Domesick, 1982; Groenewegen et al., 1987; Amaral and
Witter, 1995).
We tested the hypothesis that the a5 subunits of the CA1 and
CA3 hippocampal fields would regulate EtOH-motivated behav-
iors in the alcohol preferring (P) rat. To accomplish this, the
actions of bilateral and unilateral microinjections of RY in the
CA1 and CA3 hippocampal fields were evaluated for their capac-
ity to reduce EtOH-maintained responding. The degree of neu-
roanatomical specificity produced by RY was examined after both
bilateral and unilateral control injections into the NACC and
ventral tegmental area (VTA). Unlike the hippocampal fields,
these brain areas possess high levels of a2 and a1 subunit activity,
respectively (Wisden et al., 1992; Turner et al., 1993; Fritschy and
Mohler, 1995). The specificity of RY on consummatory respond-
ing was evaluated by determining the effects of RY in P rats
whose response rates for EtOH (10% v/v) and saccharin solutions
(0.05% w/v) were similar at basal levels.
MATERIALS AND METHODS
Subjects
Female selectively bred P (n 5 83) rats from the S47 and S48 generations
(Lumeng et al., 1995) were ;4–5 months of age at the beginning of the
experiment. During this period, the rats weighed between 195 and 265
gm. No effects of estrous cycle have been observed on EtOH drinking
patterns in female P rats (McKinzie et al., 1996), and female P rats
maintain their body weights within a range that allows for more accurate
stereotaxic placement than male P rats (Nowak et al., 1998). Animals
were individually housed in wire-mesh stainless steel cages or plastic
tubs. The vivarium was maintained at an ambient temperature of 21°C
and was on a normal 12 hr light /dark cycle. All rats were provided ad
libitum access to food and water, except during the first 2 d of the training
phase wherein rats were fluid-deprived 23 hr daily (see below). There-
after, rats were maintained on ad libitum food and water. All training and
experimental sessions took place between 10:00 A.M. and 3:00 P.M. All
procedures were conducted in strict adherence with the NIH Guide for
the Care and Use of Laboratory Animals.
Synthesis of RY 023
Isotoic anhydride was heated with sarcosine in DMSO to provide the
known intermediate 1,4-benzodiazepine. Then the aromatic ring of this
1,4-benzodiazepine was brominated by bromine in acetic acid in the
presence of sodium acetate to give the 7-bromo-1,4-benzodiazepine in
high yield. Conversion of the 7-bromo-1,4-benzodiazepine into the
8-bromoimidazobenzodiazepine was then accomplished according to the
published work of Gu et al. (1993) and Austin et al. (1981). A Heck type
coupling reaction of this 8-bromoimidazobenzodiazepine was used to
install the trimethylsilyl acetylene functionality at position 8 of the
imidazobenzodiazepine nucleus. The Heck coupling reaction provided
RY in excellent yield.
Other drugs and solutions
EtOH (10% v/v) and saccharin solutions (0.05% w/v) were prepared for
the operant chamber as described previously (June et al., 1998a,b). The
competitive BDZ antagonists ZK 93426 (ZK) (Schering, Berlin, Germa-
ny), flumazenil (Ro 15–1788), and the inverse agonist Ro 15–4513
(Hoffman La Roche, Nutley, NJ) were donated as gifts.
Behavioral testing apparatus
Behavioral testing was conducted in 15 standard operant chambers
(Coulbourn Instruments, Allentown, PA) equipped with two removable
levers and two dipper fluid delivery systems enclosed in sound-attenuated
cubicles as described previously (June et al., 1998a–c). All dipper pre-
sentations provided a 1.5 sec access to a 0.1 ml dipper, followed by a 3 sec
time-out period. Above each lever, three stimulus lights (red, green, and
yellow) were present, and a stimulus delivery–reinforcer was indicated by
illumination of the middle (green) stimulus light. Responses and rein-
forcements were recorded and controlled by 486 IBM computers using
the 4.0 Coulburn L2T2 operant software package.
Behavioral training in the operant chamber
A concurrent fixed-ratio (FR) schedule was used to investigate the
capacity of direct microinjections of RY to selectively reduce EtOH and
saccharin-maintained responding. The specific details of these proce-
dures have been described recently (June et al., 1998f, 1999). In brief, rats
were initially trained to orally self-administer EtOH and water in daily 60
min sessions on a concurrent FR1 schedule. After a period of stabiliza-
tion on the FR1 schedule, the response requirement was increased to a
concurrent FR4 schedule. After stabilization on the FR4 schedule, a
series of preliminary studies were conducted to determine the saccharin
concentration that produced response rates and profiles similar to that of
EtOH (June et al., 1998f, 1999). Of the saccharin concentrations tested,
the 0.025 and 0.05% w/v concentrations produced response rates and
profiles of responding that were similar to those of EtOH (see below).
Stabilization on the concurrent FR4 schedule for EtOH and the saccha-
rin concentrations (0.05% or 0.025% w/v) was conducted for 3–4 addi-
tional weeks before beginning the drug treatment phase. Responding was
considered stable when responses were within 620% of the average
responses for 5 consecutive days. The position of the levers and associ-
ated dippers for each reinforcer was alternated on each session to control
for the establishment of lever preference under all concurrent schedules.
The importance of alternative and concurrently presented reinforcers in
examining the positive reinforcing properties of drugs of abuse has been
discussed previously (Carroll et al., 1989; Heyman and Oldfather, 1992;
Meisch and Lemaire, 1993) (for a more recent discussion, see June et al.,
1998f, 1999; Rodefer et al., 1999).
Experiments 1 and 2 (Microinjection studies)
Assignment to surg ical groups. Because only selected rats, despite exten-
sive training, were capable of lever pressing concurrently for EtOH (10%
v/v) and a saccharin reinforcer at relatively similar rates of responding,
only rats that evidenced response rates of at least 65–80% of the
alternative reinforcer were selected to evaluate the drug treatments (for
more details, see June et al., 1998f, 1999). Using this criterion, 83 rats
were selected to participate in the study. Of these, 14 rats lever pressed
for 10% (v/v) EtOH and 0.05% (w/v) saccharin at similar rates, whereas
the remaining 69 lever pressed for 10% (v/v) EtOH and 0.025% (w/v)
saccharin at similar rates. Of the 69 rats, 14 were then randomly assigned
to the hippocampal group, 14 to the VTA group and 14 to the NACC
group. These rats were used in experiment 1 for bilateral implantation.
From the remaining 27 rats, nine were randomly assigned to a second
hippocampal group, nine to a second VTA group, and nine to a second
NACC group. These rats were used in experiment 2 for unilateral
implantation. The unilateral study was conducted to determine whether
occupancy of GABAA receptors containing a5 subunits in a single
hemisphere would be sufficient to produce antagonism of EtOH-
maintained responding. Previously, we reported that unilateral injections
in the NACC of nonselective imidazobenzodiazepines were capable of
producing antagonism of EtOH-motivated responding (June et al.,
1998a).
Implantation of guide cannulas. Standard stainless steel guide cannulas
(26 gauge) were stereotaxically implanted bilaterally and unilaterally in
the hippocampus [anteroposterior (AP), 24.8; mediolateral (ML), 63.0;
dorsoventral (DV) 23.8 (CA1); DV, 24.8 (CA3)], VTA [AP, 25.7; ML,
61.6; DV, 29.2], and NACC [AP, 12.0; ML, 61.4; DV, 27.2]. The
coordinates are given in millimeters relative to bregma based on the
Paxinos and Watson (1998) atlas. In the bilateral hippocampal group,
seven received implants in the CA1, whereas the remaining seven re-
ceived implants in the CA3. In the unilateral hippocampal group, five rats
received implants in the CA1, whereas the remaining four received
implants in the CA3. Rats were given 7 d to recover from surgery before
returning to training in the operant chamber.
Microinjection procedures. The infusions were delivered immediately
before the operant session with a Harvard infusion pump, during which
time animals were able to move about freely in their home cages. The
injection cannula extended 1 mm beyond the tip of the guide cannulas.
When RY was microinjected into a brain locus, it was dissolved in
artificial CSF (aCSF) (composition in mM: 120 NaCl, 4.8 KCl, 1.2
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KH2PO4, 1.2 MgSO4, 25 NaHCO3, 2.5 CaCl2, and 10 D-glucose). The
competitive BDZ antagonist ZK was prepared in a similar manner
whether given alone or in combination with RY (for details, see June et
al., 1998b). When necessary, HCl acid or NaOH was added to the
solutions to adjust pH levels to ;7.4 6 0.1. RY (0–40 mg) or aCSF was
infused bilaterally for 5 min at a rate of 0.1 ml /1 min using a 28 gauge
injector cannula. The injector cannula was connected by polyethylene
tubing to a 10 ml Hamilton microsyringe. The injection volume delivered
to each hemisphere was 0.5 ml, with a total injection volume for both the
left and right hemispheres of 1 ml. Thus, if a rat received a drug treatment
of 20 mg, both the left and right hemispheres received 10 mg in a volume
of 0.5 ml. Rats receiving unilateral infusions received their drug dose in
a total injection volume of 1 ml. After completion of the 5 min infusion
period, the injector was left in place for an additional 1 min to allow
diffusion from the needle tip. In experiment 1, the competitive,
b-carboline BDZ antagonist ZK (7 mg) (see Jensen et al., 1984; Duka et
al., 1987; Duka and Dorow, 1995) was given 5 min before the RY (20 mg).
When the combination treatment was given, rats were placed in the
operant boxes immediately after infusion of the RY. The dose range of
RY was selected based on previous research in our laboratory evaluating
the actions of unilateral and bilateral infusions of RY in selected brain
loci (June et al., 1998e; Foster et al., 1999). The 20 mg RY dose was
selected for antagonism by the competitive BDZ antagonist because it
produced the greatest reduction of EtOH and saccharin-maintained
responding in both our preliminary work (Foster et al., 1999) and the
present study. The dose of the BDZ antagonist was selected based on our
preliminary work showing it was effective in antagonizing the EtOH
suppression of other imidazobenzodiazepine inverse agonists (our un-
published data). To control for carry-over effects, subsequent pretreat-
ments were not administered until both EtOH and saccharin responding
had returned to their predrug baseline levels for at least 3 d, with a
minimum of 3 d between all drug treatments. All aCSF and drug
treatments were administered in a randomize design in each experiment.
Rats received a maximum of seven bilateral infusions in experiment 1
and six unilateral infusions in experiment 2.
Histology. After the completion of the behavioral testing, animals were
killed by CO2 inhalation. Cresyl violet (0.5 ml) was injected into the
infusion site, and the brains were removed and frozen. The frozen brains
were sliced on a microtome at 50 mm sections, and the sections were
stained with cresyl violet acetate. Infusion sites were examined under a
light microscope and indicated on drawings adapted from the rat brain
atlas of Paxinos and Watson (1998). Rats with improper placements were
excluded from the final data analysis.
Blood–alcohol concentration measurement. To ensure that animals were
consuming pharmacologically relevant amounts of EtOH during operant
sessions, blood–alcohol concentrations (BACs) were collected in a subset
of animals on days animals did not receive drug treatment. After the first
30 min of an operant session, ;100 ml of whole blood was collected from
the rats’ tail tip into a heparin-coated microsample tube. The BAC
samples were collected at the 30 min time point because the majority of
EtOH-maintained responding typically occurred during the first half of
the 1 hr operant session (June et al., 1998a,b). After collection, the whole
blood was immediately centrifuged for 5 min at 1100 rpm. Plasma
samples of 5 ml were collected with a Gilson Medical Electric (Middleton,
WI) Microman M-25 pipette and injected directly into a GL-5 Analyzer
(Analox Instruments, Luxenburg, MA). Microanalysis consisted of mea-
suring the oxygen consumption in the reaction between the sample of
alcohol and alcohol oxidase using a Clark-type amperometric oxygen
electrode. Alcohol reagent buffer solutions (pH 7.4) and alcohol oxidase
enzymes were used in all samples tested. Results were calculated in units
of milligram per deciliter and printed within 20 sec of each trial. To
ensure accuracy of measurement, each BAC sample was calibrated twice.
The mean of the two samples was used as an index of the level of BAC
content for a given rat. Single-point calibrations were performed using 5
ml of aqueous 100 mg/dl (21.7mmol/ l) standard.
Statistical analysis. All microinjection data were obtained and analyzed
after correct histological verification under a light microscope. The
operant-maintained responding data were analyzed by a single-factor
repeated-measures ANOVA with drug treatment (i.e., dose) as the
independent factor. The dependent variables were EtOH and saccharin-
maintained responding. Each dependent variable was analyzed sepa-
rately. Post hoc comparisons between individual drug treatments were
made using the Newman–Keuls test in all experiments. In general, drug
treatment comparisons were made against the aCSF control condition
and the no injection baselines (i.e., BL1 and BL2). The BL1 condition
was the average of 5 d before the animals received any drug treatment,
whereas the BL2 condition was the average of 5 d after animals received
their final drug treatment. The first day of the BL2 condition was taken
4–5 d after the rats’ final drug treatment. The BL1 and BL2 conditions
were included in the design to evaluate the reliability of our operant
training procedures across the entire duration of the study and to serve
as an additional control condition to compare our aCSF and drug
treatment manipulations. When BL1 and BL2 are depicted in the figures,
because the two did not differ statistically from each other, we will discuss
these data as a single “no injection control condition,” albeit both were
analyzed in the original study design. Finally, to determine the time
course of antagonism across the 60 min session, a drug treatment 3 time
analysis was conducted for the cumulative responses for both EtOH and
saccharin. Correlated t tests were conducted in each experimental group
to compare response rates between EtOH and saccharin-maintained
responding under baseline and aCSF conditions.
Experiment 3 (Xenopus oocyte expression study)
Materials. Xenopus laevis frogs were purchased from Xenopus-1 (Dexter,
MI). Collagenase B was purchased from Boehringer Mannheim (India-
napolis, IN). GABA was purchased from Research Biochemicals
(Natick, MA). All compounds were prepared at a 10 mM stock solution
in ethanol and stored at 220°.
cDNA clones. The rat GABAA receptor a1, a2, a5, and g2 subunit
clones were gifts from H. Luddens (Department of Psychiatry, University
of Mainz, Germany). The rat GABAA receptor b3 subunit clone was a
gift from L. Mahan (National Institute of Neurological Disorders and
Stroke, National Institutes of Health, Bethesda, MD).
Injection of in vitro synthesized RNA into Xenopus oocytes. Capped
cRNA was synthesized from linearized template cDNA encoding the
subunits using mMESSAGE mMACHINE kits (Ambion, Austin, TX).
Oocytes were injected with the a, b, and g subunits in a 1:1:1 molar ratio
as determined by UV absorbance.
Mature X. laevis frogs were anesthetized by submersion in 0.1%
3-aminobenzoic acid ethyl ester, and oocytes were surgically removed.
Follicle cells were removed by treatment with collagenase B for 2 hr.
Each oocyte was injected with 50–100 ng of cRNA in 50 nl of water and
incubated at 19° C in modified Barth’s saline (88 mM NaCl, 1 mM KCl,
2.4 mM NaHCO3, 0.41 mM CaCl2, 0.82 mM MgSO4, 100 mg/ml gentami-
cin, and 15 mM HEPES, pH 7.6). Oocytes were recorded from after 3–10
d after injection.
Electrophysiolog ical recordings. Oocytes were perfused at room tem-
perature in Warner Instruments (Hamden, CT) oocyte recording cham-
ber #RC-5/18 with perfusion solution (in mM: 115 NaCl, 1.8 CaCl2, 2.5
KCl, and 10 HEPES, pH 7.2) (Harvey et al., 1997). Perfusion solution
was gravity fed continuously at a rate of 15 ml/min. Compounds were
diluted in perfusion solution and applied until after a peak current was
reached.
Current responses to GABA application were measured under two-
electrode voltage clamp, at a holding potential of 260 mV. Data were
collected using a GeneClamp 500 amplifier and Axoscope software
(Axon Instruments, Foster City, CA). GABA concentration–response
curves for the GABAA receptor subunit combinations were constructed
by normalizing responses to a low concentration of GABA to minimize
variability and then renormalized to the maximal response for compar-
ison. Concentration–response data were fitted to a four-parameter lo-
gistic using GraphPad Prizm, and the EC50 for each receptor subtype was
determined. Peak whole-cell current responses of a voltage-clamped
oocyte to an EC50 concentration of GABA in the presence of saturating
(1–10 mM) concentrations of modulators are reported as a percentage of
the peak response to GABA alone (“percent GABA response” or “%
control”).
RESULTS
Experiment 1: bilateral study
Histologies
Figure 1A–D shows a reconstruction of serial coronal sections of
the rat brain illustrating the location of the bilateral microinjec-
tion cannulas in the CA1 and CA3 hippocampus (A, B), NACC
(C), and VTA (D). Figures 2A–F and 3A–D show examples of
representative photomicrographs for the three groups illustrating
the extent of the lesions sustained as a result of the bilateral guide
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cannula. The cannula tracks were well localized in the CA1 or
CA3 fields of the hippocampus, NACC, and VTA.
Control rates of EtOH and saccharin-maintained responding
and BAC levels
Figure 4A–C shows that EtOH and saccharin-maintained re-
sponding within each group were similar in the bilateral hip-
pocampus, NACC, and VTA groups under the control conditions
( p . 0.05). The BACs (i.e., in milligrams per deciliter) in the
hippocampal rats (24.4–83.37 mg/dl) (n 5 6) correlated signifi-
cantly with EtOH-maintained responding and intake (i.e., in
grams per kilogram) (r 5 0.98, p , 0.01 and r 5 0.99, p , 0.0,
respectively). The BACs in the VTA rats (18.6–92.46 mg/dl)
(n 5 8) were also highly correlated with EtOH-maintained re-
sponding and intake (r 5 0.98, p , 0.01 and r 5 0.99, p , 0.01,
respectively). However, in the NACC rats (n 5 8), the correla-
tions between the BACs (12.6–94.75 mg/dl) and EtOH-
maintained responding and intake (r 5 0.52, p . 0.10 and r 5
0.50, p . 0.23, respectively) did not reach statistical significance.
RY drug treatments
Hippocampus. Figure 4A shows rates of responding maintained
by EtOH (top panel) after microinjection of the 1.5–20 mg doses
of RY. RY produced a dose-related suppression on EtOH-
maintained responding. A highly significant main effect of drug
treatment emerged from these data (F(6,54) 5 9.07, p , 0.0001).
The Newman–Keuls post hoc tests revealed that all doses signif-
icantly suppressed EtOH responding compared with the aCSF
Figure 1. Reconstruction of serial coro-
nal sections of the rat brain illustrating the
bilateral guide cannula tips for hippocam-
pal (n 5 9) (A, B), NACC (n 5 9) (C), and
VTA (n 5 10) (D) rats included in the
data depicted in Figure 4 A–C. Each rat is
represented by two solid black circles: one
in the left and one in the right hemi-
sphere. Coronal sections are adapted
from the rat brain atlas of Paxinos and
Watson (1998), reproduced with permis-
sion from Academic Press.
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and baseline conditions ( p # 0.01). The bottom panel of Figure
4A shows rates of responding maintained by saccharin. The 10 mg
dose elevated saccharin-maintained responding, whereas the 20
mg dose produced a marked suppression on responding ( p ,
0.01). These findings yielded a significant main effect of drug
treatment (F(6,54) 5 3.36, p , 0.0069).
Cumulative response profiles: time course effects of RY
Figure 4B illustrates the cumulative response profiles for EtOH
under the aCSF, no injection control (e.g., BL and BL2), and RY
treatment conditions. Approximately 45% of the total EtOH-
maintained responding occurred during the initial 10 min of the
operant session, and 88% occurred by the end of the 30 min
interval under the control conditions. All RY doses disrupted the
initiation of responding during the first 10 min of the operant
session ( p # 0.05) and, thereafter, produced sustained suppres-
sion throughout the remainder of the 60 min session ( p # 0.05).
A significant drug treatment 3 time interaction emerged from
these data (F(6,30) 5 8.98, p , 0.0001). Figure 4C illustrates the
cumulative response profiles for saccharin. Approximately 36%
of the total saccharin-maintained responding occurred during the
initial 10 min interval, whereas 76% occurred by the end of the 30
min under the control conditions. The 10 mg dose significantly
elevated saccharin responding throughout the entire 60 min in-
terval ( p # 0.05), whereas the 20 mg dose significantly suppressed
saccharin-maintained responding throughout the 20–60 min in-
tervals ( p # 0.05). These data profiles produced a significant drug
treatment 3 time interaction (F(6,30) 5 3.43, p , 0.001).
Evaluation of the competitive BDZ antagonist (ZK) to
attenuate the RY-induced suppression of EtOH and saccharin-
maintained responding
In Figure 4A the b-carboline antagonist ZK (7 mg) and the
combination condition (i.e., 7 mg ZK plus 20 mg RY) were
compared with the aCSF and two BL control conditions. ZK was
effective in reversing the attenuation produced by the 20 mg dose
of RY ( p , 0.01), and when given alone, it also suppressed
EtOH-maintained responding ( p , 0.01). These data profiles
yielded a significant main effect of drug treatment (F(4,36) 5 6.401,
p , 0.0005). The bottom panel of Figure 4A depicts the actions of
ZK alone (7 mg) and in combination with the 20 mg dose of RY
on saccharin-maintained responding. These data show that ZK
also attenuated the RY-induced suppression on saccharin-
maintained responding ( p , 0.05). However, given alone, ZK did
not alter saccharin-maintained responding ( p . 0.05).
Figure 2. Representative histological
photomicrographs for four rats illus-
trating coronal sections of the CA1
(dorsal) and CA3 (ventral) hippocam-
pus. The photomicrographs depicts
the guide cannula tracks and the mag-
nitude of cellular damage caused by
the bilateral cannula implantation.
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Neuroanatomical control sites: NACC and VTA
Figure 5A shows rates of responding maintained by EtOH (top
panel) and saccharin (bottom panel) after microinjection of the
0.5–20 mg doses of RY into the NACC. Compared with the aCSF
and BL control conditions, none of the RY treatments altered
EtOH or saccharin-maintained responding (F(7,56) 5 0.737, p .
0.05 and F(7,56) 5 0.805, p . 0.05, respectively). A similar profile
of effects were observed in the VTA for EtOH and saccharin-
maintained responding (F(5,45) 5 0.215, p . 0.05 and F(5,45) 5
0.907, p . 0.05, respectively).
Experiment 2: unilateral study
Histologies
Figure 6A–C shows a reconstruction of serial coronal sections of
the rat brain illustrating the location of the unilateral microinjec-
tion cannulas in the CA1 and CA3 hippocampus (A), NACC (B),
Figure 3. Representative histological
photomicrographs of coronal sections
for the NACC (n 5 2) (A, B) and VTA
(n 5 2) (C, D) rats. A and C depict the
cellular damage caused by the bilateral
cannula implantation, and B and D
show the effects of the unilateral
implantation.
Figure 4. Dose–response of bilateral infusions of RY (0.0–20 mg) in the hippocampus (n 5 9) ( A), NACC (n 5 9) ( B), and VTA (n 5 10) (C) on a
concurrent fixed-ratio (FR4) schedule for EtOH (10% v/v) and saccharin-maintained (0.025% w/v) (SACC) responding. Immediately after the
microinfusions, rats were placed in the operant chamber to lever press for a 60 min session. *p # 0.05 versus the no injection control conditions (BL1
and BL2) and aCSF control condition values by ANOVA and post hoc Newman–Keuls test (n 5 9). Error bars represent 6SEM in this and subsequent
figures. †p , 0.01 versus the 20 mg RY alone condition by ANOVA and post hoc Newman–Keuls test (n 5 9). ZK, the competitive BDZ antagonist,
completely reverses the suppression by RY on EtOH and saccharin-motivated responding. RY was without effect on EtOH or saccharin-maintained
responding in the NACC and VTA (see Materials and Methods).
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and VTA (C). Representative photomicrographs are depicted in
Figures 2 and 3.
Control rates of EtOH and saccharin-maintained responding
and blood EtOH concentration levels
Figures 7A–C shows that EtOH and saccharin-maintained re-
sponding were similar in the hippocampal and VTA groups ( p .
0.05); however, the NACC group responded significantly higher
for the saccharin reinforcer ( p , 0.05). The BACs in the hip-
pocampal rats (n 5 7) correlated significantly with EtOH-
maintained responding and intake (r 5 0.95, p , 0.01 and r 5
0.95, p , 0.0, respectively). The BACs in the NACC (n 5 5) and
VTA (n 5 5) rats were also correlated with EtOH-maintained
responding and intake (r 5 0.77, p , 0.05 and r 5 0.79, p , 0.05;
r 5 0.71, p , 0.05 and r 5 0.75, p , 0.05, respectively).
RY drug treatments
Hippocampus. Figure 7A (top panel) shows that unilateral micro-
injection of RY produced a clear dose-dependent suppression on
EtOH-maintained responding, yielding a highly significant main
effect of drug treatment (F(5,30) 5 42.28, p , 0.0001). Compared
with the aCSF control condition, responding was reduced by
36–86% with the 1–40 mg doses ( p , 0.01). The bottom panel of
Figure 7A shows that only the 40 mg dose nonselectively sup-
pressed responding maintained by saccharin ( p , 0.01). This
finding yielded a significant main effect of drug treatment (F(5,30)
5 4.91, p , 0.0002).
Neuroanatomical control sites: NACC and VTA
Figure 7, B and C, shows rates of responding maintained by EtOH
(top panel) and saccharin (bottom panel) after unilateral micro-
injection of the 0.01–20 mg doses of RY into the NACC and VTA,
respectively. Compared with the aCSF control condition, none of
the RY treatments altered EtOH or saccharin-maintained re-
sponding in the NACC (F(4,16) 5 0.394, p . 0.05 and F(4,16) 5
1.56, p . 0.05) or VTA (F(4,16) 5 0.779, p . 0.05 and F(4,16) 5
0.770, p . 0.05, respectively).
Experiment 3: Xenopus oocyte expression study
Because efficacy is defined by subunit composition (von Blanken-
feld et al., 1990; Wong and Skolnick, 1992; Graham et al., 1996)
and the VTA, NACC, and hippocampus contain high levels of the
a1, a2, and a5 subunits, respectively, (Wisden et al., 1992; Dun-
Figure 5. Cumulative time course profile across the 60 min interval for
EtOH (A) and saccharin-maintained (B) responding relative to the
control conditions [i.e., aCSF and no injection control (e.g., BL and BL2)].
All RY doses disrupted the initiation of responding during the first 10 min
of the operant session and, thereafter, produced sustained suppression
throughout the remainder of the 60 min session ( p # 0.05). RY was
without effect on saccharin-maintained responding during the initial 10
min for the 1.5, 5, and 20 mg doses ( p . 0.05); however, beginning at the
20 min interval and throughout the remainder of the 60 min session, the
20 mg dose produced a profound suppression on responding ( p # 0.05).
In contrast, the 10 mg dose significantly elevated saccharin responding
across the entire 60 min session ( p , 0.05).
Figure 6. Reconstruction of serial coronal sections of the rat brain illustrating the unilateral guide cannula tips for hippocampal (n 5 7) (A), NACC
(n 5 5) (B), and VTA (n 5 5) (C) rats included in the data depicted in Figure 7A–C. Each rat is represented by one solid black circle: one in the left
or in the right hemisphere. Coronal sections are adapted from the rat brain atlas of Paxinos and Watson (1998), reproduced with permission from
Academic Press.
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can et al., 1995; Fritschy and Mohler, 1995; Charlton et al., 1997),
we determined whether the failure of RY to reduce EtOH-
maintained responding in the VTA and NACC was attributable
to it exhibiting a “different” modulation at the a1 and a2 receptor
subtypes than the a5 receptor. To determine this, the efficacy of
RY was examined at recombinant GABAA receptors composed
of a1b3g2, a2b3g2, and a5b3g2 subunits expressed in Xenopus
oocytes. The anti-alcohol compound Ro 15–4513 (Suzdak et al.,
1986) and several “neutral” competitive BDZ antagonists (e.g.,
flumazenil and ZK) were used as reference compounds. The
Xenopus system is a useful tool for functional determination of
the efficacy of GABAergic modulators (Puia et al., 1991).
Activities of GABA modulators at recombinant
GABAA receptors
Receptors containing different GABAA a subunits (a1, a2, and
a5) were coexpressed with both the b3 and g2 subunits. To
accurately compare modulator activity between receptor sub-
types, we used an equi-effective (EC50) concentration of GABA
for each GABAA receptor subtype: 50 mM for a1b3g2 and
a2b3g2, and 30 mM for a5b3g2. All modulators were examined at
saturating concentrations, either 1 or 10 mM.
Figure 8A shows that RY acted as a negative modulator at the
a1, a2, and a5 receptor subtypes, inhibiting GABA-evoked cur-
rent responses of voltage-clamped Xenopus oocytes by ;40–55%.
The relative magnitude of GABA inhibition at the a5 and a1
receptors is also depicted by the current traces illustrated in
Figure 9, A and D. For comparison, the activity of the nonselec-
tive BDZ-positive modulator flunitrazepam is illustrated at both
receptor subtypes in Figure 9, C and F. In contrast, flunitrazepam
produced a 50% potentiation of GABA-evoked currents at the a5
and a1 receptor subtypes (155 6 5 and 163 6 7%, respectively).
The efficacy of the imidazobenzodiazepines Ro 15–4513 and
Ro 15–1788 (flumazenil) were also examined at the a1b3g2,
a2b3g2, and a5b3g2 receptors (Fig. 8C,D). These parent com-
pounds were selected because we were interested in evaluating
the degree to which modification at position 8 (which produced
the a5 selectivity) (Lui et al., 1995, 1996) would change the
capacity of imidazobenzodiazepine to modulate GABA at spe-
cific receptor subtypes. Ro 15–4513 was also selected because we
were interested in comparing the intrinsic activity of a reference
alcohol antagonist (Suzdak et al., 1986; Harris and Lal, 1988;
Jackson and Nutt, 1995) with RY 023. It should be noted that the
capacity of Ro 15–4513 and flumazenil to produce intrinsic
effects at many of the GABAA-containing subunits are not
known. As shown in Figure 8C, Ro 15–4513 produced a very
modest inhibition of GABA current at the a1 and a2 subtypes
(86 6 3 and 93 6 1% control response, respectively) but exhibited
no efficacy at the a5 receptor (99.5 6 4.1% control response).
Figure 8D depicts the efficacy of the competitive antagonist
flumazenil (Ro15–1788) (Haefely, 1983, 1985, 1990). Ro 15–1788
acted as a modest positive modulator at the a2 subtype (115 6
4% control response) and exhibited no efficacy at either the a1 or
a5 subtypes. In contrast, Figure 8B shows that ZK, the compet-
itive b-carboline antagonist (Jensen et al., 1984; Duka et al., 1987;
Duka and Dorow, 1995), acted as a positive modulator potenti-
ating GABA-evoked current responses at a1- and a2-containing
receptors (146 6 11 and 140 6 13% of control, respectively);
however, ZK had no efficacy at the a5 receptor subtype (95 6 6%
of control). As illustrated in Figure 9, E and F, the relative
magnitude of GABA potentiation by ZK was comparable with
that of the full BDZ agonist flunitrazepam at the a1 receptor.
DISCUSSION
Microinjection studies
The results of the present study support the hypothesis that
GABAA receptors containing a5 subunits in the CA1 and CA3
hippocampal fields play an important role in regulating EtOH-
seeking behaviors in the genetically selected P rat. The intrahip-
pocampal modulation of EtOH-maintained responding was site-
specific; no antagonism by RY was observed after intra-NACC
and intra-VTA infusions (i.e., two brain areas reported to play a
significant role in regulating alcohol-motivated behaviors) (Koob
and Bloom, 1988; Koob et al., 1998; McBride and Li, 1998). The
reliability of the dose–effect analyses was confirmed by corre-
spondence between the bilateral and unilateral infusions. It is
possible that fewer GABAA receptors containing a5 subunits
Figure 7. Dose–response of unilateral infusions of RY (0.0–40 mg) in the hippocampus (n 5 7) (A), NACC (n 5 5) (B), and VTA (n 5 5) (C) on a
concurrent fixed-ratio (FR4) schedule for EtOH (10% v/v) and saccharin-maintained (0.025% w/v) (SACC) responding. Immediately after the
microinfusions, rats were placed in the operant chamber to lever press for a 60 min session. *p # 0.05 versus the aCSF control condition values by
ANOVA and post hoc Newman–Keuls test. Again, RY failed to alter EtOH or saccharin-maintained responding in the NACC and VTA.
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were occupied after unilateral infusions; thus, a higher dose was
required to observe the same magnitude of antagonism seen after
the bilateral infusions.
The GABA–BDZ systems have been implicated in the regula-
tion of consummatory behavioral processes (Higgs and Cooper,
1995). However, RY produced a differential sensitivity in sup-
pressing EtOH compared with saccharin-motivated responding.
Specifically, unilateral and bilateral infusions were more effective
in suppressing EtOH compared with saccharin-maintained re-
sponding (Figs. 4A, 7A). These results are consistent with our
systemic studies wherein EtOH and saccharin response rates were
equally matched at basal levels (Foster et al., 1999; June et al.,
1999). The nonselective suppression seen by RY with the higher
doses is likely attributable to occupancy of multiple a subtype
receptors. Hence, the results suggest that it is unlikely that the
RY-induced suppression of EtOH responding was attributable to
a general suppression on consummatory behaviors.
The bilateral and unilateral neuroanatomical control data re-
vealed that RY infusions produced little effects on EtOH or
saccharin-maintained responding in the NACC and VTA. These
findings suggest that (1) these brain loci are devoid of a5 recep-
tors or (2) the paucity of a5 receptors in these brain loci are not
sufficient to regulate EtOH and saccharin-maintained respond-
ing. However, it should be noted that infusion of nonselective
BDZ inverse agonists in the NACC and VTA have been reported
to produce suppression on EtOH responding (June et al.,
1998a,c). Thus, the NACC and VTA do, in fact, regulate EtOH
responding via GABAergic mechanisms, possibly via other a
receptor subtypes.
ZK, the competitive BDZ antagonist, reversed the antagonism
produced by RY on both EtOH and saccharin-maintained re-
sponding. Hence, the suppression by RY appears to be mediated
via an action at the BDZ component of the GABA complex.
Given alone, ZK also produced a marked reduction on EtOH
responding; however, it did not alter saccharin responding. That
a low dose (7 mg) of ZK was capable of producing suppression on
EtOH responding in the hippocampus [despite its low affinity at
the a5 receptor; IC50 of ;170 nM (I. Pribilla and M. Hillmann,
personal communication, Schering, Berlin, Germany)] suggests
that blockade of multiple a receptor subtypes (e.g., a12a5) may
be responsible for its suppression on EtOH-maintained respond-
ing. Nevertheless, these findings are in agreement with our pre-
vious research with systemic and oral administration of ZK (June
et al., 1996, 1998b,d).
The a5 receptors within the hippocampus may reduce
EtOH-maintained responding by interfering with
conditioned stimuli
BDZs have long been proposed to modulate learning and mem-
ory processes via the hippocampus (Izquierdo and Medina,
1991). GABAergic mechanisms in the hippocampus also appear
to mediate associations between conditioned and unconditioned
stimuli (Phillips and LeDoux, 1992). Samson and Hodge (1996)
proposed that response latency (i.e., the delay from the beginning
Figure 8. A–D, Actions of GABAA receptor modulators on recombinant
receptor subtypes. Modulation of GABAA a1b3g2 (white bar), a2b3g2
(hatched bar), and a5b3g2 (black bar) receptors by RY ( A), ZK (B), Ro
15–4513 (C), and Ro 15–1788 (D). Saturating concentrations (1–10 mM)
of modulator was coapplied over voltage-clamped oocytes along with an
EC50 of GABA, and the whole-cell current response in the presence of
modulator is reported as a percentage of the current response to GABA
alone (percent GABA response, mean 6 SD of 3–4 separate oocytes
except for ZK on a6b3g2, which is 7 separate oocytes).
Figure 9. A–F, Actions of RY, ZK, and flunitrazepam on recombinant
GABAA receptor subtypes illustrated by current traces. Top, Current
responses of voltage-clamped oocytes expressing GABAA a5b3g2 recep-
tors. A, During application of 30 mM (EC50 ) GABA alone for duration
indicated by black bar (lef t trace). Current response from the same oocyte
subsequently coapplied with 30 mM GABA along with 10 mM RY for
duration indicated by gray bar (right trace). B, Current response of a
voltage-clamped oocyte during application of 30 mM GABA for duration
indicated by black bar (lef t trace). Current response from same oocyte
subsequently coapplied with 30 mM GABA along with 10 mM ZK for
duration indicated by gray bar (right trace). C, Current response of a
voltage-clamped oocyte during application of 30 mM GABA for duration
indicated by black bar (lef t trace). Current response from same oocyte
subsequently coapplied with 30 mM GABA along with 1 mM flunitrazepam
(FNP) for duration indicated by gray bar (right trace). Bottom, Current
responses of voltage-clamped oocytes expressing GABAA a1b3g2 recep-
tors. D, During application of 50 mM (EC50 ) GABA for duration indicated
by black bar (lef t trace). Current response from same oocyte subsequently
coapplied with 50 mM GABA along with 10 mM RY for duration indicated
by gray bar (right trace). E, Current response of a voltage-clamped oocyte
during application of 50 mM GABA for duration indicated by black bar
(lef t trace). Current response from same oocyte subsequently coapplied
with 50 mM GABA along with 10 mM ZK for duration indicated by gray bar
(right trace). F, Current response of a voltage-clamped oocyte during
application of 50 mM GABA for duration indicated by black bar (lef t
trace). Current response from same oocyte subsequently coapplied with
50 mM GABA along with 1 mM flunitrazepam (FNP) for duration indi-
cated by gray bar (right trace). Calibration: A, 10 nA, 10 sec; B–F, 25 nA,
10 sec.
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of alcohol availability to the onset of responding) is an index of
“initial appetitive processes” and that conditioned stimuli may
play a role in initiating the onset of lever-press responding.
Hence, decrements, or elevations in response latency, may be
indicative of appetitive brain mechanisms. Samson and Hodge
(1996) further proposed that conditioned stimuli during the “ear-
ly maintenance phase” (i.e., 15–20 into the operant session) may
also be paired with the CNS pharmacological effects of alcohol on
previous consummatory occasions. Thus, both conditioned rein-
forcers and the CNS pharmacological effects of alcohol may
reinforce EtOH-maintained responding. If the a5 receptors
within the CA1 and CA3 hippocampal fields were functionally
involved in regulating conditioned and unconditioned stimuli
during the early phases of EtOH-maintained responding, it can be
hypothesized that RY might reduce EtOH responding by inter-
fering with–reducing conditioned cues that would normally be
present during the operant session to sustain EtOH responding. It
should be recalled that RY produced profound reductions on the
onset of alcohol drinking and led to early termination of respond-
ing (Fig. 4B). Thus, blockade of the CNS pharmacological effects
alone by EtOH may not fully explain the mechanisms by which
RY reduces EtOH-seeking behaviors.
More recently, the hippocampus, and afferents to the hip-
pocampus, have been proposed to play a role in the cognitive
aspects of anxiety (Crestani et al., 1999; McNaughton, 1999).
Thus, the reduction in alcohol drinking by RY may be related to
a reduction in anxiety attributable to the ability of RY to function
as an agonist at the a3, a4, and a6 subunits. Previous reports
reveal that negative BDZ modulators can exhibit agonist effects at
some receptor subtypes (Wong and Skolnick, 1992; Wafford et al.,
1993). However, this does not seem likely because recent work in
our laboratory has shown that RY also exhibits a classic inverse
agonist profile at the a3, a4, and a6 receptor subtypes (Foster et
al., 1999).
The a5 receptors within the hippocampus may interact
with mesolimbic dopamine systems
Another possible mechanism by which RY reduces EtOH-
seeking behaviors is that blockade of the a5 subtype receptors
initiates tonic inhibition of dopamine (DA) neurons at the hip-
pocampal level. RY may “mimic” the actions of EtOH on the DA
system. Because the DA release induced by RY would replace–
substitute the DA normally produced by EtOH responding, less
alcohol would subsequently be ingested in the presence of RY
(McBride and Li, 1998; Nowak et al., 1998). Systemic adminis-
tration of BDZ inverse agonists have been shown to increase DA
and its metabolites in subcortical and cortical areas (Scheel-
Kruger, 1986; Giorgi et al., 1988; Bradberry et al., 1991; McCul-
lough and Salamone, 1992) (for review, see Bruno and Miller,
1995). A related hypothesis may explain the capacity of ZK to
attenuate EtOH-maintained responding. It should be recalled
that, at the a1 and a2 receptor subtypes, ZK exhibited full
agonist effects (Figs. 8B, 9E).
Subunit selectivity versus intrinsic activity
Previously, we reported that rank order potencies of BDZs to
attenuate EtOH intake were not correlated with rank order
potencies of BDZs to inhibit GABA 36Cl2 conductance and
enhance 35S-t-butylbicyclophosphorothionate (TBPS) binding
(June et al., 1995). Whereas the 36Cl2 flux and TBPS binding
assays use heterogenous subunit populations, with the resulting
value obtained representing an “average efficacy,” the Xenopus
oocyte system permits efficacy to be determined at any different
subunit–cDNA combinations (Pritchett et al., 1989; Wafford et
al., 1993).
In the present study, at saturating concentrations, Ro 15–4513
was essentially neutral at the a2 and a5 receptors and slightly
negative at the a1 receptor. These data are in agreement with
previous oocyte studies (Wafford et al., 1993; June et al., 1998g)
and work by Wong and Skolnick (1992) using the GABA shift
assay. However, the findings with Ro 15–4513 contrast those with
RY and ZK, in which the GABA-evoked current is negatively
and positively modulated, respectively, at the a1 and a2 receptor
subtypes. Nevertheless, despite the three different intrinsic activ-
ity profiles, each ligand is highly effective in attenuating EtOH-
motivated behaviors (Rassnick et al., 1993; June et al., 1994,
1995a, 1998a,b). Thus, although both efficacy and subunit selec-
tivity may interact to effectively alter EtOH-motivated behaviors,
subunit selectivity may be the critical factor in determining the
capacity of a ligand to function as an effective alcohol antagonist.
Several investigators suggest that efficacy is not only dependent
on subunit composition but is actually defined by it (von Blan-
kenfeld et al., 1990; Wong and Skolnick, 1992; Graham et al.,
1996; Skolnick et al., 1997). Thus, efficacy may have little meaning
without subunit selectivity (P. Skolnick, personal communication).
Summary
These findings provide the first demonstration that GABAA
receptor-containing a5 subunits in the hippocampus play a critical
role in regulating some aspects of alcohol seeking behavior. The
precise GABA–hippocampal pathway(s) in which RY attenuates
EtOH reinforcement is not known; however, GABAA–BDZ neu-
roanatomical circuits within the hippocampus may initiate acti-
vation of underlying DA substrates in the mesoaccumbens cir-
cuitry to contribute to the reinforcing properties of EtOH. The
functional role of conditioning stimuli in the onset and mainte-
nance phases of alcohol drinking may also be important. Never-
theless, we propose that the GABA–hippocampal pathway may
represent an “extension” of the mesolimbic EtOH reward cir-
cuitry and may be an important target in the development of
potential pharmacotherapies for alcohol addiction and depen-
dence. The Xenopus oocyte studies demonstrated that the capac-
ity of BDZs to attenuate EtOH-motivated responding was not
directly related to their intrinsic efficacy; rather, their selectivity
and differential potency to attenuate EtOH-seeking behaviors
appear to be more related to their affinity and selectivity at
different GABAA-containing receptor subunits.
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